menu
    • menu
    [{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Kinnate Biopharma","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Acquisition","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0.02,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.02,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Kinnate Biopharma","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Kinnate Biopharma"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Not Applicable","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2023","type":"Not Applicable","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Not Applicable","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Not Applicable"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"XOMA","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Acquisition","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ XOMA","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ XOMA"},{"orgOrder":0,"company":"Kinnate Biopharma","sponsor":"Pierre Fabre","pharmaFlowCategory":"D","therapeuticArea":"Oncology","country":"","productType":"Small molecule","year":"2024","type":"Agreement","leadProduct":"Exarafenib","moa":"","graph1":"Oncology","graph2":"Phase I","graph3":"Kinnate Biopharma","amount2":0.029999999999999999,"highestDevelopmentShortName":"Ph I","therapeuticAreaShortName":"Oncology","amount2New":0.029999999999999999,"dosageForm":"","sponsorNew":"Kinnate Biopharma \/ Pierre Fabre","highestDevelopmentStatusID":"6","companyTruncated":"Kinnate Biopharma \/ Pierre Fabre"}]

    Find Clinical Drug Pipeline Developments & Deals for Exarafenib

    Menu

    Exarafenib

    DEVELOPMENTS

    DIGITAL CONTENT

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Pierre Fabre

                            Deal Size : $30.5 million

                            Deal Type : Agreement

                            DEALS_DEV arrow-down

                            Kinnate Biopharma Sells Investigational Pan-RAF Inhibitor Exarafenib to Pierre Fabre

                            Details : Through the agreement, Pierre Fabre will access development and global commercialization of Exarafenib, an investigational pan-RAF inhibitor evaluated for NRAS-mutated melanoma.

                            Brand Name : Exarafenib

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            March 01, 2024

                            Lead Product(s) : Exarafenib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Pierre Fabre

                            Deal Size : $30.5 million

                            Deal Type : Agreement

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : XOMA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kinnate Biopharma to Be Acquired By XOMA Corporation for Up to $2.5879 Per Share

                            Details : XOMA gains access to KIN-2787 (exarafenib), a potent and selective investigational small molecule pan-RAF inhibitor, being evaluated for BRAF/NRAS-mutated advanced or metastatic solid tumors.

                            Brand Name : KIN-2787

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 16, 2024

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : XOMA

                            Deal Size : Undisclosed

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            03

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            First Report of Positive Dose Escalation Data Supports Best-in-Class Profile for Investigational Exarafenib as...

                            Details : KIN-2787 (exarafenib) is an orally administered, potent and selective investigational small molecule pan-RAF inhibitor, designed to target BRAF Class II and Class III alterations, it is a potential treatment for NRAS mutation-positive melanoma.

                            Brand Name : KIN-2787

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            April 17, 2023

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            04

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Kinnate Biopharma

                            Deal Size : $24.0 million

                            Deal Type : Acquisition

                            DEALS_DEV arrow-down

                            Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Ven...

                            Details : KIN-2787, is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.

                            Brand Name : KIN-2787

                            Molecule Type : Small molecule

                            Upfront Cash : Undisclosed

                            February 21, 2023

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Kinnate Biopharma

                            Deal Size : $24.0 million

                            Deal Type : Acquisition

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            05

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed

                            Kinnate Biopharma

                            U.S.A arrow
                            American Pharma Summit
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Study Phase : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            DEALS_DEV arrow-down

                            Kinnate Biopharma Inc. Announces Acquisition of Ownership Stake from Series A Investors of the China Joint Ven...

                            Details : KIN-2787 (exarafenib), is an orally available small molecule pan-RAF inhibitor being developed for the treatment of patients with lung cancer, melanoma, and other solid tumors.

                            Brand Name : KIN-2787

                            Molecule Type : Small molecule

                            Upfront Cash : Not Applicable

                            February 21, 2023

                            Lead Product(s) : Exarafenib,Binimetinib

                            Therapeutic Area : Oncology

                            Highest Development Status : Phase I

                            Sponsor : Not Applicable

                            Deal Size : Not Applicable

                            Deal Type : Not Applicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth